TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.2032
-0.0130 (-6.01%)
At close: Oct 23, 2026, 4:00 PM EDT
0.2052
+0.0020 (0.98%)
After-hours: Oct 23, 2026, 4:01 PM EDT
TScan Therapeutics Revenue
TScan Therapeutics had revenue of $1.05M in the quarter ending June 30, 2026, a decrease of -65.83%. This brings the company's total for the last twelve months to $7.11M, up 2.15% year-over-year. In the year 2025, TScan Therapeutics had annual revenue of $10.33M with 266.65% growth. That makes TScan Therapeutics the 38,760th largest company in the world by revenue and 5,110th in the United States.
Revenue (ttm)
$7.11M
Revenue Growth
+2.15%
P/S Ratio
1.94
Revenue / Employee
$51,529
Employees
138
Market Cap
13.77M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.33M | 7.51M | 266.65% |
| Dec 31, 2024 | 2.82M | -18.23M | -86.62% |
| Dec 31, 2023 | 21.05M | 7.51M | 55.52% |
| Dec 31, 2022 | 13.54M | 3.39M | 33.47% |
| Dec 31, 2021 | 10.14M | 9.06M | 834.65% |
| Dec 31, 2020 | 1.09M | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cerenome | 4.20M |
| Dyadic International | 3.80M |
| SeaStar Medical Holding | 1.71M |
| Allarity Therapeutics | 345.00K |
| Kiora Pharmaceuticals | 20.00K |
| Fractyl Health | 3.00K |
| BioCardia | 3.00K |
TCRX News
- 8 days ago - TScan Therapeutics Proxy statement: Proxy filing - Filings
- 6 weeks ago - TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 7 weeks ago - TScan downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 7 weeks ago - Needham downgrades TScan Therapeutics as company reprioritizes - TheFly
- 7 weeks ago - TScan Therapeutics downgraded to Hold from Buy at Needham - TheFly
- 7 weeks ago - TScan Therapeutics downgraded to Neutral from Outperform at Wedbush - TheFly
- 7 weeks ago - TScan Therapeutics Transcript: Study update - Transcripts
- 7 weeks ago - TScan Therapeutics Press release: Study update - Filings